Key Insights

Highlights

Treatment Research

1 treatments under study, led by Zvs106e

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Early Phase 1 (1)

Trial Status

Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT07241169Early Phase 1RecruitingPrimary

The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4

NCT06435000RecruitingPrimary

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Showing all 2 trials

Research Network

Common Treatments

  • Zvs106e1

Active Sponsors

  • Splice Bio1
  • Zhongshan Ophthalmic Center, Sun Yat-sen University1
  • Chigenovo Co., Ltd1

Top Investigators

Related Conditions

  • Stgd11
  • Stargardts Disease1
  • Stargardt Disease1

Activity Timeline